Siyamemazin, Blonanserin ve Nemonaprid'in Farelerde Vas Deferens Kasılmaları Üzerine Etkileri

Abstract

Öz: Amaçlar: Antipsikotik ilaçların yaygın olarak cinsel işlev bozukluğu ile ilişkili olduğu bilinmektedir. Ancak atipik antipsikotik ilaçların bu etkilerine ilişkin çalışmalar oldukça sınırlıdır. Bu çalışmanın amacı, fare vas deferensinin serotonin (5-HT), noradrenalin (NA), adenozin trifosfat (ATP) ve potasyum klorür (KCl) ile indüklenen kasılmaları üzerine siyamemazin, blonanserin ve nemonaprid'in etkilerini araştırmaktır. Gereç ve Yöntemler: Bu çalışmada erkek kendi içinde yetiştirilmiş fareler kullanılmıştır. Fareler rastgele deney gruplarına (n=7) şu şekilde ayrıldı: salin; siyamemazin 0,25 mg/kg; siyamemazin 0,50 mg/kg; blonanserin 0,5 mg / kg; blonanserin 1 mg/kg; nemonaprid 0,5 mg / kg; nemonaprid 1 mg / kg. Farelere, 21 gün boyunca ilaçlar intraperitoneal olarak uygulandı. 21 gün boyunca %0.9 salin alan fareler kontrol grubunu oluşturdu. 21 günlük tedaviden sonra, ilaçların etkileri, fare vas deferensinin epididimal ve prostatik bölümlerine 5-HT, NA, ATP ve KCl'nin neden olduğu kasılma tepkileri araştırıldı. Bulgular: Siyamemazin ve blonanserin ile tedavi edilen fare vas deferenslerinin hem epididimal ve hem de prostatik kısımlarında, 5-HT ile indüklenen kasılma tepkileri anlamlı bir şekilde arttı. Ayrıca, siyamemazin, blonanserin ve nemonaprid uygulanan fare vas deferenslerinin prostatik ve epididimal kısımları; NA, ATP, KCl ile indüklenen kasılmaları önemli ölçüde değiştirmedi. Sonuçlar: Bu sonuçlar, vas deferens'in serotonin kaynaklı kasılmalarının, kronik siyamemazin ve blonanserin tedavilerinden etkilendiğini, ancak nemonapridden etkilenmediğini gösterdi. Ancak bu ilaçların NA, ATP ve KCl ile indüklenen kasılmalar üzerinde önemli bir etkisi yoktu. Serotonerjik reseptörler, kronik ciamemazin ve blonanserin tedavisi gören farelerde vas deferens kasılmalarındaki değişikliklere katkıda bulunabilir. Bu nedenle, sonuçlarımız, siyamemazin ve blonanserin'in neden olduğu cinsel işlev bozukluğunun nedenlerinden birini açıklayabilir.

Keywords

• siyamemazin
• blonanserin
• nemonaprid
• erektil disfonksiyon

Effects of Cyamemazine, Blonanserin and Nemonapride on Mice Isolated Vas Deferens Contractility

Abstract

Abstract: Objectives: Antipsychotic drugs are known to be commonly associated with sexual dysfunction. However, studies on the effects of atypical antipsychotic drugs are very limited. The aim of this study to investigate the effects of cyamemazine, blonanserin and nemonapride on serotonin (5-HT), noradrenaline (NA), adenosine triphosphate (ATP) and potassium chloride (KCl)-induced contractions of the vas deferens in mice. Material and Methods: Male inbred mice were used in this study. The mice were randomly divided into experimental groups (n=7) as follows: saline; cyamemazine 0,25 mg / kg; cyamemazine 0,50 mg / kg; blonanserin 0,5 mg / kg; blonanserin 1 mg / kg; nemonapride 0,5 mg / kg; nemonapride 1 mg / kg. Mice were treated by ip injection of drugs for 21 days. Mice receiving only the vehicle (0.9% saline, i.p.) during 21days served as control group. After 21 days of treatment, the effects of drugs were investigated on 5-HT, NA, ATP and KCl-induced contractile responses in the epididymal and prostatic portions of mice vas deferens strips. Results: 5-HT-induced contractile responses were significantly increased in both the epididymal and prostatic portions of mice vas deferens in cyamemazine and blonanserin but not nemonapride-treated groups. In addition, NA, ATP and KCl-induced contractions did not significantly alter contractile responses of prostatic and epididymal portions of mice vas deferens in cyamemazine, blonanserin, and nemonapride-treated groups. Conclusions: These results showed that serotonin-induced contractions of vas deferens were affected by the chronic treatments of ciamemazine and blonanserin but not nemonapride. All drugs had no significant effect on NA, ATP and KCl-induced contractions of mice vas deferens. Serotonergic receptors may contribute to changes in vas deferens contractions in mice with chronic treatment of ciamemazine and blonanserin. Thus, our results may explain one of the causes of sexual dysfunction of ciamemazine and blonanserin.

Keywords

• cyamemazine
• blonanserin
• nemonapride
• erectyle dysfunction

References

1. 1-El Kissi 2011 El Kissi Y, Mannai J, Laroussi M, Gaabout S, Ayachi M, Hadj Ali B. P03-209-Sexual function in untreated then treated schizophrenic patients: a prospective study. European Psychiatry. 2011; Vol. 26:1378.
2. 2-Nicolaou 2012 Nicolaou L. Sexual dysfunction in people with schizophrenia. Mental Health Practice. 2012;15(10):20-4.
3. 3- Murphy AZ, Rizvi TA, Ennis M, Shipley MT. The organization of preoptic-medullary circuits in the male rat: evidence for interconnectivity of neural structures involved in reproductive behavior, antinociception and cardiovascular regulation. Neuroscience. 1999; 91:1103-16.
4. 4- Chen CY, Lane HY, Lin CH. Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender Differences. Clinical Psychopharmacology Neuroscience. 2016; 14(3):238–249.
5. 5- Waldinger MD. Psychiatric disorders and sexual dysfunction. Handbook of Clinical Neurology. 2015; 130:469–89.
6. 6- Clayton AH, Alkis AR, Parikh NB, Votta JG. Sexual Dysfunction Due to Psychotropic Medications. Psychiatric Clinics of North America. 2016; 39(3):427-63.
7. 7- Giuliano F, Clément P. Physiology of ejaculation: emphasis on serotonergic control. European Urology. 2005; 48:408-17.
8. 8- El-Hamd MA, Saleh R, Majzoub A. Premature ejaculation: an update on definition and pathophysiology. Asian Journal of Andrology. 2019; 21(5):425–432.

9. 9- Marrit KB, Castelein S, Wiersma D, Schoevers R, Knegtering H. The Facts About Sexual Dysfunction in Schizophrenia: An Overview of Clinically Relevant Findings. Schizophrenia Bulletin. 2015; 41(3):674–686.
10. 10- Murasaki M, Nishikawa H, Ishibashi T. Dopamine-serotonin antagonist: receptor binding profile of a novel antipsychotic blonanserin. Jpn J Clin Psychopharmacol. 2008; 11:845–854. In Japanese.
11. 11- Baba S, Enomoto T, Horisawa T, Hashimoto T, Ono M. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range. J Pharmacol Sci. 2015; 127: 326–331.
12. 12- Frank I. Tarazi, Ph.D., Sylva K. Yeghiayan, Ph.D., Ross J. Baldessarini, M.D., Nora S. Kula, M.S., and John L. Neumeyer, Ph.D. Long-Term Effects of S(1)N-n-Propylnorapomorphine Compared with Typical and Atypical Antipsychotics: Differential Increases of Cerebrocortical D2-Like and Striatolimbic D4-Like Dopamine Receptors. Neuropsychopharmacology. 1997; Vol. 17, No. 3.
13. 13- Shunyu Li, Jin-Ho Song, Tae Im Kim, Won Gi Yoo, Moo-Ho Won, Fuhong Dai, Sung-Jong Hong. Chemotactic migration of newly excysted juvenile Clonorchis sinensis is suppressed by neuro-antagonists. PLoS Negl Trop Dis. 2019; Aug; 13(8): e0007573.
14. 14- World Health Organisation-DSM-IV, 2000.
15. 15- Rocco SC, Cacciola A, Bruschetta D, Milardi D, Quattrini F, Sciarrone F, et al. Neuroanatomy and function of human sexual behavior: A neglected or unknown issue? Brain and Behavior. 2019; 9(12): e01389.
16. 16- Gillman N, Gillman M. Premature Ejaculation: Aetiology and Treatment Strategies. Medical Sciences. 2019; 7(11):102.
17. 17- Gray M, Zillioux J, Khourdaji I, Smith RP. Contemporary management of ejaculatory dysfunction. Translational Andrology and Urology. 2018; 7(4):686–702.
18. 18- Murad Atmaca. Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: Current Management Perspectives Neuropsychiatr Dis Treat. 2020; 16: 1043–1050.
19. 19- Clément P, Bernabé J, Gengo P, Denys P, Laurin M, Alexandre L, et al. Supraspinal site of action for the inhibition of ejaculatory reflex by dapoxetine. European Urology. 2007; 51:825-32.
20. 20- Giuliano F. 5-hydroxytryptamine in premature ejaculation: opportunities for therapeutic intervention. Trends in Neurosciences. 2007; 30:79–84.